Cardiol Therapeutics Inc.

Cardiol Therapeutics is a leader in producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease.

Recent News

  • Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

    Oakville, Ontario--(Newsfile Corp. - July 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure, announces today that David Elsley, President and CEO of ...

    2019-07-25 9:53 AM ET
  • Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

    Oakville, Ontario--(Newsfile Corp. - June 20, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial ...

    2019-06-20 9:06 AM ET
  • Cardiol Therapeutics Reports Results of its AGM

    Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, ...

    2019-06-13 4:39 PM ET
  • Cardiol Therapeutics to Webcast Annual General Meeting on June 12

    Oakville, Ontario--(Newsfile Corp. - June 10, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it will be webcasting the informal portion of ...

    2019-06-10 11:03 AM ET
  • Cardiol Therapeutics' Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD

    Oakville, Ontario--(Newsfile Corp. - June 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer ...

    2019-06-03 8:03 AM ET
  • Cardiol Therapeutics Commences Trading on the OTCQX

    Oakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it has qualified to trade on the OTCQX® ...

    2019-05-30 8:33 AM ET
  • Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A

    Oakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and development of pharmaceutical cannabidiol and targeted therapies for inflammatory disease, today announced the filing of its audited year-end financial statements and management's discussion and analysis for the ...

    2019-03-28 8:47 AM ET
  • Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer

    Oakville, Ontario--(Newsfile Corp. - March 6, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, is pleased to announce the appointment of Thomas (Tom) Moffatt, BBA, as ...

    2019-03-06 9:37 AM ET